Bisphosphonate compositions and methods for treating heart failure

Abstract

The present invention provides for methods and compositions for treating and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof.

That which is claimed is: 
     
         1 . An oral or liquid composition comprising zoledronic acid in a therapeutically effective amount to increase ejection fraction in a treated subject, wherein the therapeutically effective amount is formulated to deliver from about 40 ug/kg to about 125 ug/kg to a subject. 
     
     
         2 . The composition of  claim 1 , wherein the amount of zoledronic acid is about 100 ug/mg. 
     
     
         3 . The composition of  claim 1 , wherein the ejection fraction is increased in the left ventricle. 
     
     
         4 . The composition of  claim 1 , further comprising at least one other therapeutic agent selected from the group consisting of nitrates, beta-adrenergic blockers, angiotensin converting enzyme inhibitors, calcium channel antagonists, antihypertensive agents, cholesterol lowering agents, diuretics, ACE inhibitors, cardiac glycosides, non-peptide angiotensin II antagonists, IIb/IIIa antagonists and aspirin. 
     
     
         5 . The composition of  claim 1 , further comprising Vitamin D. 
     
     
         6 . A kit for treatment or prevention of heart failure and negative side-effects thereof, the kit comprising at least one dose of a bisphosphonate in an therapeutically effective amount to treat or prevent the symptoms of heart failure, wherein the therapeutically effective amount is formulated to deliver from about 40 ug/kg to about 125 ug/kg to a subject. 
     
     
         7 . The kit of  claim 6 , further comprising a dosage of Vitamin D for consumption from 1 day to one month.